Background: Despite a second-line treatment with fingolimod (FNG), some patients with relapsing-remitting Multiple Sclerosis (RR-MS) may have residual disease activity. The current therapeutic strategy is based on the switch to either natalizumab (NTZ) or anti-CD20 (rituximab or ocrelizumab). To date the relative effectiveness of these two...
-
October 13, 2021 (v1)PublicationUploaded on: November 8, 2024
-
2020 (v1)Journal article
Background: Longitudinally extensive transverse myelitis (LETM) is classically related to aquaporin (AQP4)-antibodies (Ab) neuromyelitis optica spectrum disorders (NMOSD) or more recently to myelin oligodendrocyte glycoprotein (MOG)-Ab associated disease. However, some patients remain negative for any diagnosis, despite a large work-up...
Uploaded on: December 4, 2022 -
2019 (v1)Journal article
BACKGROUND:Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease.METHODS: This is a retrospective...
Uploaded on: December 4, 2022 -
January 2023 (v1)Journal article
Objective: The objective of this study was to develop evidence-based recommendations on pregnancy management for persons with multiple sclerosis (MS). Background: MS typically affects young women in their childbearing years. Increasing evidence is available to inform questions raised by MS patients and health professionals about pregnancy...
Uploaded on: March 2, 2023